|Day Low/High||1.22 / 1.26|
|52 Wk Low/High||0.99 / 2.71|
Initial data from Phase 1b study in NASH
Insiders at these companies are scooping up shares of their own stock lately.
Durect Corp.'s (DRRX) licensee Pain Therapeutics (PTIE) new drug application for an opioid analgesic was denied by the FDA.
Here's a technical look at how to trade some of the most active stocks on the market right now.
Investors in Durect Corp saw new options begin trading today, for the April 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Pain Therapeutics Announced today that an FDA Advisory Committee Meeting for REMOXY® is Not Needed and No Change to September 25, 2016 PDUFA Date
FDA's Tentative Date for Advisory Committee Meeting is August 5, 2016 and No Change to PDUFA Date of September 25, 2016
Stocks with insider trader activity include SMLP, DRRX and MDSO
Stocks with insider trader activity include DRRX, EA and KAI
Single-Ascending-Dose Study in NASH Patients
Initial Phase 1 Safety Studies Successfully Completed, Positioning for the Start of Patient Studies in 2016